Project Grant HT9425261E186
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $348K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $349,976 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2028. The award funds research focused on intercepting omental metastasis of ovarian cancer through targeting a mitochondrial redox-interleukin-10 (IL-10) axis in the immune microenvironment. This research initiative...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $893,525 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research titled "Targeting Neuronal Mimicry in SMARCB1-Deficient Renal Medullary Carcinoma Treatment," which investigates novel therapeutic approaches to address renal medullary...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $5.47M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2029. The award funds research aimed at targeting ganglioside GD2 to overcome chemotherapy resistance in triple-negative breast cancer. This research initiative represents translational and clinical investigation...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $817,496 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $414,472 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research targeting neuronal mimicry in SMARCB1-deficient renal medullary carcinoma (RMC) treatment. This three-year initiative delivers translational research and therapeutic development services...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $560K project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2026, with completion targeted for August 31, 2028. The award funds research on modulating hypoxia-activated stromal programs to potentiate chimeric antigen receptor T (CAR-T) cell therapy in kidney cancer. This translational oncology research...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $559,968 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2028. The award supports research focused on targeting ALCAM/CD6 signaling to overcome Bacillus Calmette-Guérin (BCG) resistance in non-muscle invasive bladder cancer. This research initiative aims to develop innovative...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $490,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The grant funds research combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition to develop novel immunotherapy approaches for pancreatic...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $932,350 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2025, through August 14, 2028. The grant supports the development and evaluation of an in situ tumor vaccine designed to stimulate antitumor immunity against breast cancer. This three-year research initiative will be conducted at MD...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $735,751 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The award supports research and development activities focused on combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition as an...